肠康方对腹泻型肠易激综合征大鼠SP,VIP的影响

Effect of Changkang Formula on SP and VIP in Rats with Diarrhea-predominant Irritable Bowel Syndrome

目的:观察肠康方对腹泻型肠易激综合征大鼠血浆P物质(SP)和大鼠组织血管活性肠肽(VIP)含量的变化,探讨肠康方对腹泻型肠易激综合征的治疗效果。方法:将60清洁级雄性SD大鼠随机分为正常组、模型组、马来酸曲美布汀组,肠康方低、中、高剂量组。除正常组外,其余各组均采用番泻叶刺激加束缚应激的方法 4周,复制腹泻型肠易激综合征模型,造模成功后开始给药,马来酸曲美布汀组ig马来酸曲美布汀15 mg·kg-1,肠康方低、中、高剂量组分别予以肠康方1.1,2.2,4.4g·kg-1ig给药,正常及模型组ig等体积的生理盐水,每日1次,连续给药3周。给药结束后,进行腹壁撤退反射(AWR)评分,并采集腹主动脉血和盲肠上结肠组织,用酶联免疫分析法测定血浆SP和结肠组织VIP的含量。结果:与正常组比较,模型组大鼠AWR评分,血浆SP水平明显上升(P<0.01),结肠VIP含量显著下降(P<0.05);与模型组比较,肠康方高、中、低剂量组AWR评分明显降低(P<0.01,P<0.05),血浆SP水平明显降低(P<0.05),肠康方高、中剂量组结肠VIP含量明显升高(P<0.01,P<0.05)。结论:肠康方可能通过改善内脏高敏感性、降低血浆中SP的含量和升高结肠黏膜中VIP的含量,治疗腹泻型肠易激综合征。

Objective ： To study the effects of Changkang formula （CF） on plasma P substance （SP） and colon vasoactive intestinal peptide （VIP） in rats with diarrhea-predominant irritable bowel syndrome （D-IBS） , and to explore its possible mechanism on D-IBS. Method： Sixty Sprague-Dawley rats were randomly divided into 6 groups： the normal control group （normal saline）, model group （normal saline）, the maleate trimebutine group （15 mg·kg^-1）, the low-, middle and high-dose CF groups （1. 1, 2. 2, 4. 4 g·kg^-1）. The D-IBS model was induced in rats by senna-free drinking and stress-restrainting for 4 weeks. The corresponding medicines were intragastrically administered to rats once daily for 3 weeks. The abdominal withdrawal reflex （AWR） was scored. The levels of SP in serum and VIP in tissue were detected by using the ELISA assay. Result： Compared with the normal group, AWR score and plasma SP level increased, colon VIP level decreased in the model group （P 〈0.05, P 〈0.01 ）. Compared with the model group, AWR score and plasma SP level decreased, colon VIP level increased in the low-, middle and high-dose CF groups （P 〈 0.05, P 〈 0. 01 ）. Conclusion ： CF had a therapeutic effect on D-IBS by improving visceral hypersensitivity, reducing the level of plasma SP, and elevating the level of colon VIP in rats.